Perrigo CoMEX:PRGON 44 Current Ratio is 2.72 as of Mar. 2026, which is 30% above its 10-year median of 2.10. GuruFocus rates MEX:PRGON with a GF Score™ of 44/100 and a GF Value™ of MXN1,468.70. The stock has 4 warning signs investors should review. Among 998 Drug Manufacturers companies, Perrigo Co ranks better than 63.43% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Perrigo Co's current ratio for the quarter that ended in Mar. 2026 was 2.72.
Perrigo Co has a current ratio of 2.72. It generally indicates good short-term financial strength.
The historical rank and industry rank for Perrigo Co's Current Ratio or its related term are showing as below:
MEX:PRGON'
s Current Ratio Range Over the Past 10 Years
Min: 1.45 Med: 2.1 Max: 4.01
Current: 2.72
During the past 13 years, Perrigo Co's highest Current Ratio was 4.01. The lowest was 1.45. And the median was 2.10.
MEX:PRGON's Current Ratio is ranked better than 63.43% of 998
companies
in the Drug Manufacturers industry
Industry Median: 2
vs MEX:PRGON: 2.72
Perrigo Co (MEX:PRGON) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Perrigo Co Current Ratio Related Terms
Perrigo Co Current Ratio Historical Data
* Premium members only.
The historical data trend for Perrigo Co's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PRGON vs AMLX, HROW, ANIP: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perrigo Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Perrigo Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perrigo Co (MEX:PRGON) has a Current Ratio of 2.72 as of Mar. 2026. This is 30% above median its historical median of 2.10. Over the past decade, Perrigo Co's Current Ratio has ranged from 1.45 to 4.01. According to the industry distribution chart, Perrigo Co ranks #365 out of 998 companies in the Drug Manufacturers industry, placing it in the top 36.6%.
Is Perrigo Co's Current Ratio too high?
Perrigo Co's current Current Ratio of 2.72 is 30% above median its 10-year median of 2.10. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 4.01. The Drug Manufacturers industry median Current Ratio is 2.00. Perrigo Co's value of 2.72 is 36% above this industry median. Based on the distribution chart, Perrigo Co ranks #365 out of 998 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Perrigo Co has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Perrigo Co's Current Ratio compare to AMLX and HROW?
According to the Drug Manufacturers industry distribution chart, Perrigo Co ranks #365 out of 998 companies for Current Ratio. This puts Perrigo Co in the upper half of its industry. The industry median Current Ratio is 2.00. Perrigo Co's value of 2.72 is 36% above this benchmark. Historically, Perrigo Co's own Current Ratio has ranged from 1.45 to 4.01 over the past decade. While the company's 10-year median is 2.10 vs. the industry median of 2.00, Perrigo Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perrigo Co's current Current Ratio of 2.72 is 36% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perrigo Co's current Current Ratio is 2.72, which is 30% above median its own 10-year median of 2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perrigo Co stock overvalued right now?
Perrigo Co (MEX:PRGON) has a current Current Ratio of 2.72. The stock's GF Value™ is MXN1,468.70, compared to a current price of MXN557.52 — trading 62% below its estimated fair value. The current Current Ratio is 2.72, which is 30% above median its 10-year median of 2.10 and 36% above the Drug Manufacturers industry median of 2.00. Perrigo Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Perrigo Co (MEX:PRGON), the current Current Ratio is 2.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perrigo Co (MEX:PRGON) Overvalued in 2026?
Based on GuruFocus' analysis, Perrigo Co stock appears to be undervalued.
The current stock price of MXN557.52 is trading 62% below its estimated GF Value™ of MXN1,468.70.
Key valuation signals for MEX:PRGON:
Current Ratio: 2.72 (30% above median its 10-year median of 2.10)
GF Value™: MXN1,468.70 vs. price of MXN557.52 (62% below fair value)
Industry Position: 36% above the Drug Manufacturers median (#365 of 998)
No single metric tells the full story. See the MEX:PRGON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
44GF Score
Get the complete analysis for MEX:PRGON
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRGON has been successfully added to your 
